期刊文献+

少突胶质瘤染色体1p/19q联合缺失与Ki-67表达的关系 被引量:1

Correlation between combined deletion of chromosome 1p/19q and expression of Ki-67 in mesoglioma
下载PDF
导出
摘要 目的观察少突胶质瘤染色体1p/19q联合缺失与Ki-67蛋白表达的相关性,探索预测少突胶质瘤化疗敏感性的分子标记物。方法少突胶质瘤肿瘤组织标本31例作为实验组,少突胶质瘤瘤旁正常脑组织标本13例作为对照组,免疫组化方法检测两组Ki-67蛋白的表达,荧光原位杂交技术检测1p/19q的缺失情况。结果对照组有1例Ki-67表达呈现阳性,占7.7%,实验组有14例Ki-67表达呈现阳性,占45%,两组阳性率差异有统计学意义(P<0.05);对照组无1p/19q缺失,实验组有13例(41.9%)1p/19q联合缺失,其中1p单独缺失2例(6.4%),19q单独缺失1例(3.2%)。结果显示,Ki-67蛋白表达与1p/19q联合缺失显著相关(r=0.13,P<0.05)。结论 Ki-67蛋白表达是预测少突胶质瘤化疗敏感性的潜在分子标记物。 Objective To observe the correlation between combined deletion of chromosome 1 p/19q and expression of Ki - 67 in mesoglioma,and to explore the molecular markers forecasting chemosensitivity of mesoglioma. Methods Thirty one tumor tissue speeimens of mesoglioma were selected as experimental group, and 13 specimens of normal brain tissues adjacent to the mesoglioma were chosen as control group. Immunohistochemistry method was used to detect the expression of Ki - 67 protein in both groups, and fluorescence in situ hybridization was carried out to detect the 1 p/19q deletion. Results In the control group, the expression of Ki - 67 was positive in one case, which accounted for 7.7%. In the experimental group, the expression of Ki - 67 was positive in 14 cases, which accounted for 45 %. There were significant differences between the two groups ( P 〈 0.05 ). The control group had no 1 p/19q deletion, while the experimental group had 13 cases of 1p/19q(41.9% ) combined deletion in which two were lp single deletion(6.4% ) and one was 19q single deletion(3.2% ). The statistical analysis indicated that there was a correlation between the expression of Ki - 67 protein and the 1p/19q combined deletion(r = 0. 13, P 〈 0.05 ). Conclusion Ki - 67 protein expression is the potential molecular marker forecasting the chemosensitivity of mesoglioma.
作者 孙浩 李卫
出处 《西南国防医药》 CAS 2013年第4期366-368,共3页 Medical Journal of National Defending Forces in Southwest China
关键词 少突胶质瘤 1p 19q KI-67 相关性 mesoglioma 1p/19q Ki - 67 correlation
  • 相关文献

参考文献11

二级参考文献62

  • 1袁庆国,松本健一,岩城澈.MGMT和Ki-67在胶质母细胞瘤中的表达对ACNU化疗预后的影响[J].中国神经肿瘤杂志,2006,4(3):200-204. 被引量:4
  • 2Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol, 2005, 64:479-489.
  • 3Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes lp and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol, 1995, 54:91-95.
  • 4Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagamstic neuro-oncology. J Neuropathol Exp Neurol, 2003, 62 : 111-126.
  • 5Kros JM, Godia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neumpathol Exp Neurol, 2007, 66:545-551.
  • 6Kanner AA, Staugaitis SM, Castilla EA, et al. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome ann lp as an important factor in clinical decision making. J Neurosurg, 2006, 104:542-550.
  • 7Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology, 2007, 68 : 1831-1836.
  • 8Kim SH, Kim H, Kim TS. Clinical, histological, and immuno- histochemical features predicting 1p/19q loss of hetemzygosity in oligodendroglial tumors. Acta Neuropathol, 2005, 110:27-38.
  • 9Levin N, Lavon I, Zdikovitsh B, et al. Progressive low-grade oligedendrogliomas: response to temozolomide and correlation between genetic profile and O^6-methylguanine DNA methyltranaferase protein expression. Cancer, 2006, 106: 1759- 1765.
  • 10Jeon YK, Park K, Park CK, et al. Chromosome 1p and 19q status and p.53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. Neuropathology, 2007, 27 : 10- 20.

共引文献20

同被引文献53

  • 1Liu Y, Yah W, Zhang W, et al. MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncol Pep, 2012, 28(3):1013-1021.
  • 2Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005, 352(10):987-996.
  • 3Sulman EP, Tang XX, Allen C, et al. ECK, a human EPH-related gene, maps to lp36.1, a common region of alteration in human cancers. Genomics, 1997, 40(2):371-374.
  • 4Genander M, Fris6n J. Ephrins and Eph receptors in stem cells and cancer. Curt Opin Cell Biol, 2010, 22(5):611-616.
  • 5Miao H, Wang B. EphA receptor signaling--complexity and emerging themes. Semin Cell Dev Biol, 2012, 23(1):16-25.
  • 6Liu DP, Wang Y, Koeffler HP, et al. Ephrin-A1 is a negative regulator in glioma through down-reguation of EphA2 and FAK. Int J Oncol, 2007, 30(4):865-871.
  • 7Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res, 2008, 6(12):1795-1806.
  • 8Li X, Wang L, Gu JW, et al. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma. Tumor Biol, 2010, 31(5):477-488.
  • 9Hadjipanayis CQ Van Meir EG Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med (Bed), 2009, 87(4):363-374.
  • 10Binda E, Visioli A, Giani F, et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell, 2012, 22( 16):765-780.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部